ETNB: חוב לטווח קצר של החברה 89bio, Inc.

89bio, Inc. is implementing AI algorithms for the synthesis of drugs targeting liver pathologies while maintaining physician control over testing. Development is based on ESG principles, minimizing chemical waste and energy consumption. This chart on GURU.Markets captures the dynamics of short borrow capital, where the parameter mark equals 0.00, confirming investor confidence in the strategy of the company's experienced management.

This indicator aggregates all liabilities with a maturity of up to one year, allowing for an assessment of current solvency and default risk in the absence of operating cash flow. By analyzing the history of short-term loans and borrowings, an investor can see the dependence of 89bio, Inc. (ETNB) on external financing, which is critical given the lack of revenue and high risks of failure in clinical trials for liver disease treatments.